Biotech-Based Efferon Raises €2.5M To Expand Blood Purification Technology

Efferon develops blood purification technologies that remove endotoxins and inflammatory molecules from the bloodstream. Its product range includes Efferon LPS for adults and Efferon NEO for pediatric patients.

The company says its devices can help stabilize critically ill patients faster, potentially reducing ICU stays, ventilation time, and overall treatment costs.

Recently, Efferon received CE MDR certification for Efferon NEO, making it the first hemoadsorption device in Europe approved for neonatal and pediatric sepsis care, supported by clinical results from the LASSO NEO study.

Read Also - Manchester’s Imperagen Raises €5.7M Seed To Advance AI-Driven Enzyme Engineering

With over 25,000 treatments completed in more than 40 countries, the company is now expanding manufacturing capacity and building a new EU production facility to meet growing demand.

“Receiving CE MDR certification for Efferon NEO marks a pivotal milestone not just for Efferon, but for critical care as a whole. For the first time, clinicians across Europe have access to a multimodal extracorporeal blood purification device purpose-built for pediatric patients,” said Dima Romashin, CEO and Co-founder of Efferon. “We are entering a $40 billion market that has long been underserved by existing solutions and we are doing so with a clear mission: to bring the most advanced life-saving technology to the patients who need it most. The standard of care for a child in the ICU should be no less advanced than for any adult. We’re making sure of that with Efferon NEO.”

About Efferon

Founded in 2016 Efferon is a medical device company developing next-generation hemoperfusion technologies to treat sepsis and multiple organ failure. Its flagship product, Efferon LPS, is a single-use blood purification device approved with CE mark under EU MDR, designed to remove harmful substances from the bloodstream and improve critical care outcomes.